New combo before surgery aims to boost esophageal cancer outcomes

NCT ID NCT06078709

Recruiting now Disease control Sponsor: Mayo Clinic Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated Apr 29, 2026 · Updated 24 times

Summary

This study is for people with stage I to III esophageal or gastroesophageal junction cancer. It tests whether giving a shorter, higher-dose course of radiation along with the chemotherapy drugs FOLFOX before surgery can kill more tumor cells. The main goal is to see if this approach leads to a complete disappearance of cancer in the removed tissue. About 99 adults will take part.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CLINICAL STAGE II ESOPHAGEAL ADENOCARCINOMA AJCC V8 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Mayo Clinic in Arizona
NOT_YET_RECRUITING

Scottsdale, Arizona, 85259, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact
Mayo Clinic in Florida
ACTIVE_NOT_RECRUITING

Jacksonville, Florida, 32224-9980, United States
Mayo Clinic in Rochester
RECRUITING

Rochester, Minnesota, 55905, United States

Contact

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.